Patients must have castrate serum level of testosterone of <  ng/dL (< . nmol/L)
Evidence of castrate testosterone level <  ng/dL (or surgical castration)
Progressive metastatic prostate cancer despite castrate levels of testosterone (<  ng/dL)
Surgically or medically castrated, with testosterone ?  ng/dL (? . nmol/L).
castrate serum level of testosterone of ?  ng/dL (? . mmol/L)
Non-castrate testosterone level, >  ng/dl, at study enrollment
Documented castrate level of serum testosterone (<  ng/dl)
Patients must have castrate levels of testosterone (<  ng/dL [. nmol/L]).
Castrate testosterone level (< ng/dl or .nmol /L); (patients with a malignancy other than prostate cancer are excluded from this criterion)
Castrate testosterone level (< ng/dl or .nmol /L)
Castrate testosterone level (< ng/dl or .nmol /L)
Metastatic castration resistant prostate cancer with castrate-level testosterone (<  ng/dL)\r\n* Subjects must maintain a castrate-level testosterone during the study
Tumor progression while on hormone therapy with castrate levels serum testosterone (=< . nmol/L or  ng/dL) defined by prostate-specific antigen (PSA) and/or radiographic criteria according to the Prostate Cancer Working Group  (PCWG). Castrate levels of testosterone must be maintained by surgical or medical means throughout the conduct of the study.
Serum testosterone ? . nmol/L ( ng/dL) at screening.
Has a serum testosterone at the Screening visit of ?  ng/dL (. nmol/L);
Castrate testosterone level (<  ng/dl or . nmol/L)
mCRPC EXPANSION COHORT: Patients must have castrate levels of testosterone (<  ng/dl [. nmol/l])
Documented castrate level of serum testosterone (<  ng/dl)
Castrate level of testosterone (<  ng/dL)
Patient must be treated with continuous androgen ablative therapy (e.g. goserelin, leuprolide, triptorelin, or degarelix, if he has not had prior surgical castration) and have castrate levels of testosterone (<  ng/dL or . nmol/L)
Serum testosterone ?  ng/dL (. nmol/L).
Testosterone ?  ng/dL (? . nmol/L) at screening;
Patients must have prior and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (< ng/dL).
Patients must have a castrate level of serum testosterone (<  ng/dL)
Testosterone ? . nmol/L (?  ng/dL) at screening;
Patients must have castrate levels of testosterone (< ng/dl [. nmol/l]).
Tumor progression while on hormone therapy with castrate levels serum testosterone (=< . nmol/L or  ng/dL) defined as biopsy-proven, PSA and/or radiographic criteria according to the Prostate Cancer Working Group  (PCWG); castrate levels of testosterone must be maintained by surgical or medical means throughout the conduct of the study
Castrate levels of serum testosterone <  ng/dL determined within  weeks prior to starting treatment
Medical or surgical castration with testosterone less than  ng/dL (.nmol/L).
Serum testosterone level: ?  ng/dL (. nmol/L)
Patients must have non-castrate levels of serum testosterone (>=  ng/dL)
Testosterone =<  ng/dL (. nmol/L)
Maintain castrate levels of testosterone within  weeks prior to randomization and throughout the study
Castrate testosterone level (<  ng/dl or . nmol/L)
Castrate serum testosterone level, =< . nmol/L ( ng/dL), at the screening visit
For cohorts , , and  only: non-castrate testosterone level (>  ng/dL)
Castrate levels of serum testosterone of less than or equal to  ng/dL
Hormone-sensitive prostate cancer as evident by a serum total testosterone level >  ng/dL or >  nmol/L at the time of enrollment within  weeks prior to randomization
Testosterone ? . nmol/L (?  ng/dL) at screening.
Castrate serum testosterone (<  ng/dL)
Castrate resistant progression of prostate carcinoma, as shown by:\r\n* Serum testosterone level =<  ng/dL or prior bilateral orchiectomy; treatment to remain castrate levels of testosterone should continue, and\r\n* Either symptomatic progression, or, if patient is asymptomatic then a rising serum PSA in two occasions at least  week apart, with minimum pre-treatment serum PSA of  ng/dL
Both measurements are greater than  ng/dL or . nmol/L;
Castrate serum testosterone level: =<  ng/dL (=< . nmol/L)
Serum total testosterone >=  ng/dL (. nmol/L)